B6.129S2-WwoxGt(W088C04)Wrst/Ieg

Status

Available to order

EMMA IDEM:04729
Citation informationRRID:IMSR_EM:04729 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameB6.129S2-WwoxGt(W088C04)Wrst/Ieg
Alternative nameW088C04
Strain typeGene-trap
Allele/Transgene symbolWwoxGt(W088C04)Wrst
Gene/Transgene symbolWwox

Information from provider

ProviderJerzy Adamski
Provider affiliationIEG, HMGU
Genetic informationInactivation of the Wwox gene by integration of a lacZ cassette a the 3' end of intron 4-5.
Phenotypic informationNot yet characterised.
Breeding historyBackcrossed to C57BL/6 (5 generations), currently using heterozygous animals for breeding.
ReferencesNone available
Homozygous fertilenot known
Homozygous viablenot known
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreHelmholtz Zentrum Muenchen - German Research Center for Environmental Health (GmbH), Oberschleißheim, Germany
Animals used for archivingheterozygous C57BL/6J males, wild-type C57BL/6J females
Stage of embryos2-cell

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

    • Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency / Orphanet_284282
    • Undetermined early-onset epileptic encephalopathy / Orphanet_442835
    • 46,XY partial gonadal dysgenesis / Orphanet_251510
MGI phenotypes (allele matching)
  • no phenotypic analysis / MGI
MGI phenotypes (gene matching)
  • decreased bone mineral density / MGI
  • abnormal trabecular bone morphology / MGI
  • decreased compact bone thickness / MGI
  • hypoglycemia / MGI
  • decreased circulating calcium level / MGI
  • decreased leukocyte cell number / MGI
  • enlarged spleen / MGI
  • small spleen / MGI
  • small ovary / MGI
  • small testis / MGI
  • Leydig cell hyperplasia / MGI
  • small seminiferous tubules / MGI
  • seminiferous tubule degeneration / MGI
  • decreased body weight / MGI
  • decreased body size / MGI
  • abnormal osteoclast physiology / MGI
  • increased circulating phosphate level / MGI
  • abnormal circulating enzyme level / MGI
  • anemia / MGI
  • postnatal growth retardation / MGI
  • abnormal homeostasis / MGI
  • reduced male fertility / MGI
  • testis hypoplasia / MGI
  • neoplasm / MGI
  • increased malignant tumor incidence / MGI
  • increased tumor incidence / MGI
  • increased B cell derived lymphoma incidence / MGI
  • premature death / MGI
  • abnormal skeleton development / MGI
  • increased brain weight / MGI
  • abnormal thymus cortex morphology / MGI
  • decreased circulating triglyceride level / MGI
  • decreased circulating testosterone level / MGI
  • decreased circulating alkaline phosphatase level / MGI
  • no phenotypic analysis / MGI
  • decreased circulating bicarbonate level / MGI
  • increased circulating chloride level / MGI
  • decreased circulating chloride level / MGI
  • testicular atrophy / MGI
  • decreased liver weight / MGI
  • spleen atrophy / MGI
  • increased osteosarcoma incidence / MGI
  • abnormal compact bone morphology / MGI
  • increased incidence of tumors by chemical induction / MGI
  • decreased spleen weight / MGI
  • decreased thymus weight / MGI
  • decreased osteoblast cell number / MGI
  • increased bone resorption / MGI
  • cachexia / MGI
  • decreased circulating cholesterol level / MGI
  • increased circulating bilirubin level / MGI
  • growth/size/body region phenotype / MGI
  • reproductive system phenotype / MGI
  • decreased circulating serum albumin level / MGI
  • abnormal skeleton morphology / MGI
  • Leydig cell hypoplasia / MGI
  • decreased circulating glucose level / MGI
  • increased blood urea nitrogen level / MGI
  • decreased circulating total protein level / MGI
  • increased circulating potassium level / MGI
  • decreased circulating aspartate transaminase level / MGI
  • decreased circulating sodium level / MGI
  • abnormal pituitary gland physiology / MGI
  • increased lung tumor incidence / MGI
  • abnormal osteoblast differentiation / MGI
  • decreased survivor rate / MGI
  • increased blood uric acid level / MGI
  • increased pituitary gland weight / MGI
  • thin uterine horn / MGI
  • decreased trabecular bone thickness / MGI
  • abnormal primary ovarian follicle morphology / MGI
  • decreased theca cell number / MGI
  • increased skeletal tumor incidence / MGI
  • mortality/aging / MGI
  • decreased bone trabecula number / MGI
  • decreased trabecular bone volume / MGI
  • decreased trabecular bone connectivity density / MGI
  • decreased compact bone area / MGI
  • postnatal lethality, complete penetrance / MGI
  • increased adrenal gland weight / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).